Cell Culture Market (2026-2036)

The growth of this market is mainly driven by the expansion of biologics manufacturing, including monoclonal antibodies, antibody-drug conjugates, and therapeutic proteins, each of which consumes cell culture media and single-use consumables in proportion to production volume; the growth of cell and gene therapy manufacturing, which requires specialised media and closed-system consumables at high cost per batch; the continuing transition from serum-containing to chemically defined, serum-free, and xeno-free formulations driven by regulatory and supply considerations; and the adoption of single-use bioreactors and consumables, which converts capital equipment spending into recurring consumable demand. In addition, regulatory initiatives promoting human cell-based alternatives to animal testing, the growth of three-dimensional culture, organoid, and organ-on-chip systems, the expansion of vaccine and biosimilar manufacturing, and the build-out of biomanufacturing capacity in Asia-Pacific are further supporting the growth of this market.

The Cell Culture Market, also referred to as the cell culture consumables and equipment market, cell culture reagents market, or cell cultivation market, comprises the media, sera, reagents, vessels, bioreactors, and ancillary equipment used to grow and maintain cells outside the organism for research, diagnostic, and manufacturing purposes. The market includes classical, serum-free, chemically defined, and xeno-free media supplied in dry and liquid forms as off-the-shelf or custom formulations; animal sera and serum substitutes; growth factors and cytokines; cryoprotective reagents; antibiotics and antimycotics; cell dissociation reagents; buffers and balanced salt solutions; culture vessels, flasks, plates, and single-use bags and bioreactors; and incubators, centrifuges, biosafety cabinets, cell counters, and filtration and storage equipment. The market ecosystem extends from media, reagent, and equipment manufacturers to biopharmaceutical manufacturers, contract development and manufacturing organizations, cell and gene therapy developers, vaccine manufacturers, diagnostic companies, academic and research institutes, and the regulators whose expectations shape media composition and process design.

Cell culture is the foundation on which the biologics industry rests. Every monoclonal antibody, therapeutic protein, viral vector, and cell therapy is produced by cells growing in a defined environment, and the composition of that environment determines yield, product quality, and consistency. Media and feeds are consumed in proportion to production volume, which makes this market a direct function of biomanufacturing output rather than of instrument placement, and it is why media represents the largest single product category and the one most closely coupled to industry growth.

The market has recovered from a difficult period. Following the pandemic, biopharmaceutical manufacturers and contract manufacturers had accumulated substantial inventories of media and single-use consumables, and the subsequent destocking depressed supplier revenues for several quarters in a way that reflected inventory correction rather than any decline in underlying production. In the second quarter of 2026, Merck KGaA reported Life Science net sales of EUR 2.4 billion, up 8.0% organically, with its Process Solutions business unit growing 14.7% organically to EUR 1.07 billion, led by downstream processing and single-use solutions, and upgraded its full-year Life Science guidance to net sales of approximately EUR 9.3-9.6 billion with organic growth of 5% to 7%. In the first quarter of 2026, Sartorius AG reported group sales of EUR 899 million, up 7.5% in constant currencies, with its Bioprocess Solutions division growing 8.1% in constant currencies to EUR 735 million, and confirmed full-year guidance of constant-currency sales growth of approximately 6% to 10% for Bioprocess Solutions, driven mainly by consumables, with an underlying EBITDA margin slightly above 32%. Growth of 14.7% organically in process solutions and 8.1% in bioprocess consumables indicates that destocking has concluded and that demand now tracks production.

Cell and gene therapy manufacturing is the fastest-growing source of demand and the most demanding technically. According to a pipeline assessment published in January 2026, six cell and gene therapy products had been submitted to the U.S. Food and Drug Administration with prescription drug user fee act dates falling in 2026, with a further 18 products anticipated in 2027, of which 12 were in Phase 3. In July 2026, the U.S. Food and Drug Administration expanded the approval of CASGEVY, the first CRISPR-based gene-editing therapy, to children aged two years and older with sickle cell disease or transfusion-dependent beta thalassemia, with the therapy available at more than 75 authorized treatment centres in the U.S. These processes require media supporting the expansion of primary human cells, often without animal-derived components, in closed single-use systems and at batch sizes far smaller than antibody production, which means cost per batch is high and the media must be qualified to a standard appropriate to a product administered as a single irreversible dose.

Regulatory expectations are shaping media composition directly. In May 2026, the FDA Center for Biologics Evaluation and Research issued final guidance that removed the fixed requirement for three process performance qualification lots for process validation of cell and gene therapy products and permitted concurrent validation and release, while noting that changes in source materials, such as a switch from fetal bovine serum to human albumin, require comparability studies. The explicit identification of a change from fetal bovine serum to human albumin as requiring comparability studies illustrates how closely media composition is tied to regulatory filings, and why manufacturers prefer to establish chemically defined formulations early rather than to change them after clinical data has been generated.

A second regulatory current is expanding the research market for human cell culture. In September 2026, the FDA announced a direct final rule replacing the terms animal tests and animal studies with nonclinical tests and nonclinical studies throughout its regulations, clarifying that non-animal methods including human cell-based platforms and organ-on-chip systems can be used where appropriate to test the safety of drugs and biological products, and in June 2026 the European Commission published its roadmap towards phasing out animal testing for chemical safety assessments across 15 regulatory domains. Where safety assessment moves from animal studies toward human cell-based systems, organoids, and organ-on-chip platforms, the demand created falls on cell culture media, specialised reagents, and three-dimensional culture consumables, which positions this part of the market to benefit from a regulatory shift originating outside biomanufacturing entirely.

Capacity investment sustains the equipment and consumables cycle. In the first half of 2026, Lonza Group AG reported sales of CHF 3.4 billion, up 16.0% at constant exchange rates, with all business platforms growing at double-digit rates, raised its full-year CORE EBITDA margin guidance to 33-34%, and brought its large-scale mammalian asset in Visp, Switzerland into commercial operation as planned. New manufacturing capacity consumes equipment on commissioning and media and single-use consumables for as long as it operates, and the continuing build-out of capacity by contract manufacturers and by biopharmaceutical companies in both established and emerging markets underpins demand across the forecast period.

The market includes diversified life science suppliers such as Thermo Fisher Scientific, Merck KGaA, Danaher through Cytiva, Sartorius, Corning, Becton Dickinson, Avantor, Bio-Rad Laboratories, Agilent Technologies, Eppendorf, Greiner Bio-One, and Getinge, together with Lonza and FUJIFILM Holdings, which supply media and services alongside contract manufacturing, Miltenyi Biotec in cell therapy reagents and systems, and regional suppliers including HiMedia Laboratories. Participants compete on media performance and yield, lot-to-lot consistency, regulatory support documentation and change control, security and geographic diversity of supply, custom formulation and process development capability, single-use portfolio breadth, and total cost of ownership.

At the same time, the market faces challenges, including the volatility that inventory cycles introduce into supplier revenues, price pressure on commodity media and consumables, the cost and lead time of qualifying a media change once a process is established, continuing dependence on animal-derived serum in parts of the research market and in some manufacturing processes, supply security concerns for critical raw materials and growth factors, and the sustainability burden of single-use plastics. As a result, suppliers that combine high-performing chemically defined formulations, documented regulatory support, geographically diversified and secure supply, custom development capability, and credible sustainability programmes are expected to capture the largest share of growth over the forecast period.